Radiotherapy & Oncology
Volume 86, Issue 3 , Pages 347-353 , March 2008

Optimum dose range for the amelioration of long term radiation-induced hyposalivation using prophylactic pilocarpine treatment

  • Fred Ronald Burlage

      Affiliations

    • Department of Radiation Oncology, University of Groningen, The Netherlands
    • Corresponding Author InformationCorresponding author. Fred Ronald Burlage, Department of Radiation Oncology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
    • These authors contributed equally.
    • ,
  • Judith M. Roesink

      Affiliations

    • Department of Radiotherapy, University Hospital Utrecht, The Netherlands
    • These authors contributed equally.
    • ,
  • Hette Faber

      Affiliations

    • Department of Radiation Oncology, University of Groningen, The Netherlands
    • Department of Cell Biology, University of Groningen, The Netherlands
    • ,
  • Arjan Vissink

      Affiliations

    • Department of Oral and Maxillofacial Surgery, University of Groningen, The Netherlands
    • ,
  • Johannes A. Langendijk

      Affiliations

    • Department of Radiation Oncology, University of Groningen, The Netherlands
    • ,
  • Harm H. Kampinga

      Affiliations

    • Department of Cell Biology, University of Groningen, The Netherlands
    • ,
  • Rob P. Coppes

      Affiliations

    • Department of Radiation Oncology, University of Groningen, The Netherlands
    • Department of Cell Biology, University of Groningen, The Netherlands

Received 25 July 2007 ,Revised 5 October 2007 ,Accepted 11 October 2007.

References 

  1. Vissink A, Jansma J, Spijkervet FK, et al. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med. 2003;14:199–212
  2. Jensen AB, Hansen O, Jorgensen K, et al. Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer. Acta Oncol. 1994;33:487–491
  3. Konings AW, Coppes RP, Vissink A. On the mechanism of salivary gland radiosensitivity. Int J Radiat Oncol Biol Phys. 2005;62:1187–1194
  4. Vissink A, Burlage FR, Spijkervet FK, et al. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med. 2003;14:213–225
  5. Coppes RP, Zeilstra LJ, Vissink A, et al. Sialogogue-related radioprotection of salivary gland function: the degranulation concept revisited. Radiat Res. 1997;148:240–247
  6. Sagowski C, Wenzel S, Metternich FU, et al. Studies on the radioprotective potency of amifostine on salivary glands of rats during fractionated irradiation: acute and late effects. Eur Arch Otorhinolaryngol. 2003;260:42–47
  7. Epperly MW, Carpenter M, Agarwal A, et al. Intraoral manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) radioprotective gene therapy decreases ionizing irradiation-induced murine mucosal cell cycling and apoptosis. In Vivo. 2004;18:401–410
  8. Hakim SG, Kosmehl H, Lauer I, et al. A comparative study on the protection profile of lidocaine, amifostine, and pilocarpin on the parotid gland during radiotherapy. Cancer Res. 2005;65:10486–10493
  9. Konings AW, Faber H, Vissink A, et al. Radioprotective effect of amifostine on parotid gland functioning is region dependent. Int J Radiat Oncol Biol Phys. 2005;63:1584–1591
  10. Coppes RP, Vissink A, Zeilstra LJ, et al. Muscarinic receptor stimulation increases tolerance of rat salivary gland function to radiation damage. Int J Radiat Biol. 1997;72:615–625
  11. Roesink JM, Konings AW, Terhaard CH, et al. Preservation of the rat parotid gland function after radiation by prophylactic pilocarpine treatment: radiation dose dependency and compensatory mechanisms. Int J Radiat Oncol Biol Phys. 1999;45:483–489
  12. Coppes RP, Zeilstra LJ, Kampinga HH, et al. Early to late sparing of radiation damage to the parotid gland by adrenergic and muscarinic receptor agonists. Br J Cancer. 2001;85:1055–1063
  13. Burlage FR, Roesink JM, Kampinga HH et al. Protection of salivary function by concomitant pilocarpine during radiotherapy; a double-blind randomized, placebo controlled study. Int J Radiat Oncol Biol Phys 2007 Sep 13; [Epub ahead of print].
  14. Eisbruch A, Ship JA, Dawson LA, et al. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg. 2003;27:832–837
  15. Malouf JG, Aragon C, Henson BS, et al. Influence of parotid-sparing radiotherapy on xerostomia in head and neck cancer patients. Cancer Detect Prev. 2003;27:305–310
  16. Braam PM, Terhaard CHJ, Roesink JM, Raaijmakers PJ. Intensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:975–980
  17. Chao KSC, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys. 2001;49:907–916
  18. Vissink A, Gravenmade EJ, Konings AW, et al. An adaptation of the Lashley cup for use in rat saliva collection. Arch Oral Biol. 1989;34:577–578
  19. Coppes RP, Vissink A, Konings AW. Comparison of radiosensitivity of rat parotid and submandibular glands after different radiation schedules. Radiother Oncol. 2002;63:321–328
  20. Coppes RP, Roffel AF, Zeilstra LJ, et al. Early radiation effects on muscarinic receptor-induced secretory responsiveness of the parotid gland in the freely moving rat. Radiat Res. 2000;153:339–346
  21. Kim KH, Kim JY, Sung MW, et al. The effect of pilocarpine and atropine administration on radiation-induced injury of rat submandibular glands. Acta Otolaryngol. 1991;111:967–973
  22. Plourde D, Soltoff SP. Ouabain potentiates the activation of ERK1/2 by carbachol in parotid gland epithelial cells; inhibition of ERK1/2 reduces Na+–K+-ATPase activity. Am J Physiol Cell Physiol. 2006;290:C702–C710
  23. Burford-Mason AP, Cummins MM, Brown DH, et al. Immunohistochemical analysis of the proliferative capacity of duct and acinar cells during ligation-induced atrophy and subsequent regeneration of rat parotid gland. J Oral Pathol Med. 1993;22:440–446
  24. Lombaert IM, Wierenga PK, Kok T, et al. Mobilization of bone marrow stem cells by granulocyte colony-stimulating factor ameliorates radiation-induced damage to salivary glands. Clin Cancer Res. 2006;12:1804–1812
  25. Gornitsky M, Shenouda G, Sultanem K, et al. Double-blind randomized, placebo-controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;98:45–52
  26. Warde P, O’Sullivan B, Aslanidis J, et al. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;54:9–13
  27. Haddad P, Karimi M. A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia. Radiother Oncol. 2002;64:29–32
  28. Lajtman Z, Krajina Z, Krpan D, et al. Pilocarpine in the prevention of postirradiation xerostomia. Acta Med Croatica. 2000;54:65–67
  29. Sangthawan D, Watthanaarpornchai S, Phungrassami T. Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. J Med Assoc Thai. 2001;84:195–203
  30. Zimmerman RP, Mark RJ, Tran LM, et al. Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia. Int J Radiat Oncol Biol Phys. 1997;37:571–575
  31. Scarantino C, LeVEque F, Swann RS, White R, Schulsinger A, Hodson DI, et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. J Support Oncol. 2006;4:252–258

PII: S0167-8140(07)00520-8

doi: 10.1016/j.radonc.2007.10.011

Radiotherapy & Oncology
Volume 86, Issue 3 , Pages 347-353 , March 2008

Article Tools

* Image Usage & Resolution